- Headquarters
- Newtown Square, Pennsylvania
- Founded
- 2021
- Business Model
- B2B
- Website
- arriventbiopharma.com
- Total Funding
- $305.0M
- Last Round
- $155.0M Series BMar 2023
About
ArriVent BioPharma is a clinical-stage biopharma company focused on accelerating the global development of innovative biopharmaceutical products through strategic partnerships. They in-license promising candidates like firmonertinib (furmonertinib) and advance a pipeline of novel oncology therapeutics, including next-generation antibody drug conjugates, toward approval and commercialization.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free Account